Search This Blog

Tuesday, August 4, 2020

Tenet’s profit more than triples in Q2 thanks to COVID-19 relief funds, cost cuts

  • Tenet’s profit more than tripled to $88 million for the second quarter despite a pandemic that has strained the healthcare industry, thanks to $523 million of income from federal relief funds, along with various cost-cutting initiatives, Tenet disclosed Monday.
  • The Dallas-based hospital operator beat Wall Street expectations on earnings but missed on revenue for its second quarter, generating revenue of $3.6 billion. That’s 20% lower than the second quarter of 2019.
  • The company did not issue an updated forecast for the year after pulling its guidance in April due to the uncertainty brought on by the novel coronavirus. Its stock was down slightly in morning trading Tuesday on the results.

Despite patient volume nearly falling off a cliff in April — the month the industry was hit hardest by the virus — Tenet reported volume shot back up to near normal in June to finish out the second quarter.
In fact, hospital surgeries were just shy (90%) of pre-COVID-19 volumes in the month of June. It’s quite the turnaround from April when hospital surgeries were down to 45% of expected volume, and surgeries at Tenet’s outpatient surgery unit, USPI, were nearly wiped out altogether, though they were back up to 80% of pre-COVID-19 levels by July.
Despite an improving picture, overall same-hospital admissions declined about 20% year over year in the second quarter.
​Tenet was particularly exposed to the effects of the virus as its outpatient branch USPI operates 264 ambulatory surgical centers, along with dozens of imaging centers and surgical hospitals. That unit reported operating revenue fell nearly 30% to $368 million for the quarter. Same-facility surgical cases fell nearly 42% year over year.
CEO Ron Rittenmeyer previously said he viewed May as the “beginning of the recovery” for hospital operations. The characterization has largely played out as procedures and volumes have rebounded in the following months even as some areas of the country have seen increasing cases that threaten to slow elective volumes.
Tenet’s hospital footprint is concentrated in 10 states — Alabama, Arizona, California, Florida, Illinois, Massachusetts, Michigan, South Carolina, Tennessee and Texas — many of which are currently experiencing surging COVID-19 cases.
Brian Tanquilut, an analyst with Jefferies, noted that investors are cautiously optimistic as the rebound does provide optimism but is also mitigated by the fact that Tenet has significant exposure to hotspots, especially south Florida, San Antonio and Phoenix.
“Our volumes in July have generally held steady or improved compared to June despite the spike of COVID cases in July in many of our markets,” CFO Dan Cancelmi said during Tuesday’s call with investors.
Tenet’s lower expenses also bolstered the surge in net income. Expenses for salaries, wages, and benefits were 13% lower in the second quarter compared to the prior-year period. Supply expenses were down almost 19%.
Despite the pandemic, Tenet and its peers for-profit hospital operators have seen profits buoyed by federal relief funds, sparking significant criticism amid a historic pandemic that’s thrown an estimated 50 million Americans off their jobs and shuttered the doors of many smaller practices.
Nashville-based HCA’s second quarter net income surged 40% compared with the prior-year period. Community Health Systems reported net income of $70 million after posting a substantial loss of $167 million the prior-year period. UHS also posted a bump in its second quarter net income thanks in large part to relief funds.
As of Monday, Tenet has received $1.5 billion in advanced Medicare loans, which must be paid back by April next year, and more than $850 million in grants from congressional relief packages.

6 states band together to secure rapid COVID testing

Bipartisan governors of six states have entered into a first-of-its-kind agreement to jointly purchase rapid coronavirus testing kits.
The governors — from Virginia, Louisiana, Massachusetts, Michigan, Ohio and Maryland — said the goal of the compact is to show private companies that there is significant demand to scale up the production of these tests, which deliver results in 15 to 20 minutes.
The states will also coordinate on policies and protocols regarding the testing technology.
Additional states, cities and local governments may join the compact in the coming days and weeks, the governors said.
The states are in discussions with Becton Dickinson and Quidel — the U.S. manufacturers of antigen tests that have already been authorized by the Food and Drug Administration — to purchase 500,000 tests per state for a total of three million tests.
Five months into the pandemic, the Trump administration has yet to develop an efficient testing system. In the absence of a national testing strategy, states have been left to come up with their own plans and secure their own equipment.
Across the country, the demand for tests has outstripped supplies, creating severe shortages and delaying results for unacceptably long periods of time.
The agreement would reduce the need for states to rely on overburdened commercial labs. For example, Quest Diagnostics said this week that the average turnaround time for a test result is five days. It’s an improvement over last month, when it said average results would take more than a week, but still creates a potentially dangerous waiting period.
“With severe shortages and delays in testing and the federal administration attempting to cut funding for testing, the states are banding together to acquire millions of faster tests to help save lives and slow the spread of COVID-19,” Maryland Governor Larry Hogan (R) said in a statement.
Hogan negotiated the deal during the final days of his tenure as chairman of the National Governors Association. The Rockefeller Foundation is willing to finance the program if needed.
Rapid antigen testing may not be the most accurate, but it can be used to help detect outbreaks more quickly and expand long-term testing in congregate settings such as schools, workplaces and nursing homes.
“Widespread testing is one of the most crucial tools we have to stop the spread of this virus and save lives,” Michigan Gov. Gretchen Whitmer (D) said in a statement. “I’m hopeful that the president and Congress will follow our lead and work together on a recovery package that includes support for states like ours so we can continue to protect our families.”


Jazz Pharmaceuticals EPS beats by $0.60, beats on revenue

Jazz Pharmaceuticals (NASDAQ:JAZZ): Q2 Non-GAAP EPS of $3.71 beats by $0.60; GAAP EPS of $2.06 beats by $0.21.
Revenue of $562.4M (+5.3% Y/Y) beats by $59.21M.
R&D $78.9M vs. $63.7M consensus.

BioMarin EPS misses by $0.04, beats on revenue, expects FY20 GAAP profit

BioMarin Pharmaceutical (NASDAQ:BMRN): Q2 GAAP EPS of -$0.16 misses by $0.04.
Revenue of $429.5M (+10.8% Y/Y) beats by $12.1M.
For the FY20, BioMarin continues to expect to be profitable on a GAAP basis for the first time.

COVID-19 test demand drives Luminex Q2 sales growth

Luminex (NASDAQ:LMNX) Q2 results:
Total revenue: $109.5M (+31.8%); Assays: $61.2M (+94.9%). Sales growth driven by demand for pandemic-related tests.
Net income: $12.5M (+355.1%); EPS: $0.27 (+345.5%).
Cash flow ops: $31.3M (+430.5%).
Q3 guidance: Revenue: at least $100M (+26%). Consensus: $107M.
2020 guidance: Revenue: at least $415M (+24%). Consensus: $387M.

Novavax rebounds from vaccine data-stoked selloff on clarified safety profile

Novavax (NASDAQ:NVAX) announces positive results from the first portion of its Phase 1/2 clinical trial evaluating its COVID-19 vaccine candidate, NVX-CoV2373, with and without the Matrix-M adjuvant, in healthy adults between 18 and 59 years of age.
NVX-CoV2373 was well-tolerated with mild reactogenicity events, mostly injection site pain and tenderness, while systemic events, less frequent, included headache, fatigue and myalgia (muscle pain) after dose 1 (5 µg). Reactogenicity was greater after dose 2 (25 µg) as expected since it was a higher dose. The average duration of events was less than two days.
On the immunogenicity front, the vaccine induced 100% neutralization titers in all participants. All subjects developed anti-spike IgG antibodies after one dose while many also developed wild-type virus neutralizing antibody responses. After the second dose, all participants developed wild-type virus neutralizing antibody responses. The IgG responses were highly correlated with neutralization titers.
The company has submitted the results for publication.
Management will host a conference call today at 5:00 pm ET to discuss the results.
Although absent from the press release, eight participants had to be hospitalized as reported by STAT News.
The data have apparently spooked investors. Shares are down 29% after hours although due for a rest. The stock is up over 39-fold this year.
Update: Shares have rebounded in after-hours trading, now down only 2%, after STAT News issued a correction to its story after communicating with the company. No participants required hospitalization.

CytoDyn’s leronlimab passes safety tollgate in late-stage COVID-19 study

In its first safety review, the independent Data Safety Monitoring Committee observed no data that would justify any changes to a Phase 3 clinical trial evaluating CytoDyn’s (OTCQB:CYDY) leronlimab in severely ill and critically ill COVID-19 patients. Consequently, it recommended that the study continue unmodified.
169 subjects are currently enrolled. A full interim analysis will be performed after 195 patients are enrolled per the protocol.